Genocea Biosciences Inc (NASDAQ:GNCA) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 1,324,729 shares, a decline of 46.0% from the February 15th total of 2,451,386 shares. Currently, 6.4% of the company’s shares are sold short. Based on an average daily trading volume, of 729,413 shares, the short-interest ratio is presently 1.8 days.
Large investors have recently bought and sold shares of the stock. Ameriprise Financial Inc. boosted its position in Genocea Biosciences by 11.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock worth $119,000 after buying an additional 2,300 shares during the period. Millennium Management LLC acquired a new position in shares of Genocea Biosciences in the 4th quarter worth approximately $145,000. New York State Common Retirement Fund acquired a new position in shares of Genocea Biosciences in the 2nd quarter worth approximately $159,000. California State Teachers Retirement System acquired a new position in shares of Genocea Biosciences in the 2nd quarter worth approximately $265,000. Finally, Teachers Advisors LLC acquired a new position in shares of Genocea Biosciences in the 2nd quarter worth approximately $268,000. Institutional investors and hedge funds own 10.29% of the company’s stock.
Several brokerages recently commented on GNCA. Zacks Investment Research cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Needham & Company LLC raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research report on Tuesday, February 6th. Robert W. Baird assumed coverage on shares of Genocea Biosciences in a research report on Monday, February 12th. They issued an “outperform” rating and a $3.00 price objective on the stock. Cantor Fitzgerald assumed coverage on shares of Genocea Biosciences in a research report on Monday, March 5th. They issued an “overweight” rating and a $5.00 price objective on the stock. Finally, HC Wainwright assumed coverage on shares of Genocea Biosciences in a research report on Thursday, March 8th. They set a “buy” rating and a $5.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Genocea Biosciences currently has an average rating of “Buy” and an average target price of $4.41.
Shares of Genocea Biosciences (GNCA) opened at $1.16 on Tuesday. Genocea Biosciences has a one year low of $0.79 and a one year high of $7.29. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of -1.26. The firm has a market cap of $95.24, a P/E ratio of -0.59 and a beta of 1.31.
Genocea Biosciences (NASDAQ:GNCA) last posted its earnings results on Friday, February 16th. The biotechnology company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.03. sell-side analysts anticipate that Genocea Biosciences will post -0.55 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/20/genocea-biosciences-inc-gnca-short-interest-update.html.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.